Dr. Laurie Glimcher Named to Stand Up To Cancer Scientific Advisory Committee - Stand Up To Cancer


Posted January 27, 2020

Dr. Laurie Glimcher Named to Stand Up To Cancer Scientific Advisory Committee

LOS ANGELES – January 27, 2020 — Stand Up To Cancer (SU2C) with its Scientific Partner, the American Association of Cancer Research (AACR), announced Laurie H. Glimcher, MD, President and CEO of the Dana-Farber Cancer Institute, Director of the Dana-Farber/Harvard Cancer Center and the Richard and Susan Smith Professor of Medicine at Harvard Medical School as the newest member of the SU2C Scientific Advisory Committee (SAC). Dr. Glimcher was introduced as the SAC’s newest member at the SU2C annual Scientific Summit in Santa Monica.

“Dr. Glimcher is a distinguished scientist and powerful leader in cancer research,” said SAC Chair Phillip A. Sharp, PhD, Institute professor, Koch Institute for Integrative Cancer Research of the Massachusetts Institute of Technology (MIT), and a Nobel laureate. “Her willingness to serve as a member of the SAC, considering her many responsibilities as head of the Dana-Farber Cancer Institute, is a strong testament of Stand Up To Cancer’s value to the community.”

The SAC is composed of prestigious academic and industry leaders in cancer research. Its role is to provide insight and guidance to SU2C as an organization, setting the direction for its research initiatives, reviewing proposals for new grant awards and conducting rigorous oversight of all active grants in the SU2C portfolio.

Dr. Glimcher is internationally recognized for her research in identifying key transcriptional regulators of protective immunity and the origin of pathophysiologic immune responses underlying autoimmune, infectious and malignant diseases. Dr. Glimcher is a Member of the National Academy of Sciences, the National Academy of Medicine and the American Philosophical Society, Fellow of the American Academy of Arts and Sciences, and the former President of the American Association of Immunologists.

In addition to her research efforts, Dr. Glimcher has been a staunch proponent of improved access to care, health policy, and medical education, while simultaneously serving as a pioneering mentor and role model for cancer research trainees and for all women in science. Notably, she was the first female to be appointed as dean of Weill Cornell Medicine in New York and is the first female President and CEO of Dana-Farber Cancer Institute in Boston.

“We are honored that Dr. Glimcher has agreed to join the SAC to help guide SU2C’s extensive research portfolio,” said Sung Poblete, PhD, RN, CEO of SU2C. “Her leadership and expertise will be critical in diversifying SU2C’s scientific programming, paving the way for breakthrough research, and as SU2C implements its health equity initiative to improve diversity in cancer clinical trials, all contributing to better outcomes for patients everywhere.”

About Stand Up To Cancer
Stand Up To Cancer® (SU2C) raises funds to accelerate the pace of research to get new therapies to patients quickly and save lives now. SU2C, a division of the Entertainment Industry Foundation, a 501(c)(3) charitable organization, was established in 2008 by media and entertainment leaders who utilize these communities’ resources to engage the public in supporting a new, collaborative model of cancer research, to increase awareness about cancer prevention, and to highlight progress being made in the fight against the disease. As of December 2019, more than 1,600 scientists representing more than 180 institutions are involved in SU2C-funded research projects.

Under the direction of our Scientific Advisory Committee, led by Nobel laureate Phillip A. Sharp, Ph.D., SU2C operates rigorous competitive review processes to identify the best research proposals to recommend for funding, oversee grants administration, and ensure collaboration across research programs.

Current members of the SU2C Council of Founders and Advisors (CFA) include Katie Couric, Sherry Lansing, Kathleen Lobb, Lisa Paulsen, Rusty Robertson, Sue Schwartz, Pamela Oas Williams, and Ellen Ziffren. The late Laura Ziskin and the late Noreen Fraser are also co-founders. Sung Poblete, Ph.D., R.N., serves as SU2C’s CEO. For more information, visit StandUpToCancer.org.

About the American Association for Cancer Research
Founded in 1907, the American Association for Cancer Research (AACR) is the world’s first and largest professional organization dedicated to advancing cancer research and its mission to prevent and cure cancer. AACR membership includes 44,000 laboratory, translational, and clinical researchers; population scientists; other health care professionals; and patient advocates residing in 120 countries. The AACR marshals the full spectrum of expertise of the cancer community to accelerate progress in the prevention, biology, diagnosis, and treatment of cancer by annually convening more than 30 conferences and educational workshops, the largest of which is the AACR Annual Meeting with more than 22,500 attendees. In addition, the AACR publishes eight prestigious, peer-reviewed scientific journals and a magazine for cancer survivors, patients, and their caregivers. The AACR funds meritorious research directly as well as in cooperation with numerous cancer organizations. As the Scientific Partner of Stand Up To Cancer, the AACR provides expert peer review, grants administration, and scientific oversight of team science and individual investigator grants in cancer research that have the potential for near-term patient benefit. The AACR actively communicates with legislators and other policymakers about the value of cancer research and related biomedical science in saving lives from cancer. For more information about the AACR, visit AACR.org.

# # #

Stand Up To Cancer
Jane Rubinstein

Zeno Group for Stand Up To Cancer
Hannah Bursack
312.396.9799 ofc, 312.868.3817 cell

American Association for Cancer Research
Richard L. Lobb


Sign up to receive emails from Stand Up To Cancer.
   Please leave this field empty
Stand Up to Cancer

Thanks for signing up!
You will hear from us soon.